Retatrutide is the drug of the future Drug maker Eli Lilly has released sneak-peek findings from the Phase 3 trial, and retatrutide benefits seem wildly impressive so far
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel: +82-31-787-8133, E-mail: [email protected] Copyright 2025 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Large-scale body modifications require precise anesthesia management, meticulous fluid balance monitoring, and pristine sterile fields
If you are in need of assistance please feel free to fill out our contact us page